

Original Paper

# Entire Peroxidation Reaction System of Myeloperoxidase Correlates with Progressive Low-Density Lipoprotein Modifications via Reactive Aldehydes in Atherosclerotic Patients with Hypertension

Quan Liu<sup>a</sup> Yawen Liu<sup>b</sup> Jikang Shi<sup>b</sup> Ming Gao<sup>a</sup> Yunkai Liu<sup>a,c,d</sup> Yetong Cong<sup>e</sup>  
Yong Li<sup>b</sup> Yonggang Wang<sup>a</sup> Mingxi Yu<sup>b</sup> Yuping Lu<sup>b</sup> Dahai Wang<sup>a</sup> Shan Chen<sup>a</sup>  
Yang Zheng<sup>a</sup> Yi Cheng<sup>a,c,d</sup>

<sup>a</sup>The Cardiovascular Center, First Hospital of Jilin University, Changchun, <sup>b</sup>Department of Epidemiology and Biostatistics, School of Public Health of Jilin University, Changchun, <sup>c</sup>Key Laboratory for Cardiovascular Mechanism of Traditional Chinese Medicine, First Hospital of Jilin University, Changchun, <sup>d</sup>Laboratory for Cardiovascular Diseases, Institute of Translational Medicine, First Hospital of Jilin University, Changchun, <sup>e</sup>The General Hospital of Jilin Chemical Group Corporation, Jilin, China

## Key Words

Myeloperoxidase • Reaction system • Lipoprotein • Atherosclerosis • Hypertension

## Abstract

**Background/Aims:** Reactive oxygen species (ROS) contribute to the dysfunction of serum lipoproteins, which triggers lipid metabolism abnormalities in the development of atherosclerosis and hypertension. Myeloperoxidase (MPO) is involved in ROS modifications, triggering lipid peroxidation and aldehyde formation. However, the relationship between the entirety of the MPO reaction system and oxidative modification of serum lipoproteins in atherosclerotic patients with hypertension remains unclear. **Methods:** We measured MPO activity (peroxidation and chlorination), 4-hydroxynonenal-modified low-density lipoprotein (HNE-LDL), malondialdehyde-modified low-density lipoprotein (MDA-LDL), H<sub>2</sub>O<sub>2</sub>, reduced glutathione (GSH), and oxidized glutathione (GSSG) using a corresponding commercial kit in atherosclerotic patients with hypertension and healthy participants. We used Spearman's correlation analysis to investigate the correlation between MPO activity and the levels of these oxidative and anti-oxidative stress-related indices and performed response surface regression to investigate the relationship between the MPO reaction system and the levels of HNE-LDL, MDA-LDL, and the GSH/GSSG ratio. **Results:** Our results showed no association between the levels of MPO peroxidation activity, MPO chlorination activity, H<sub>2</sub>O<sub>2</sub>, and Cl<sup>-</sup> and those of HNE-

Q. Liu and Y. Liu contributed equally to this work.

Yi Cheng

The Cardiovascular Center, First Hospital of Jilin University  
71 Xinmin Street, Changchun, Jilin Province 130021 (China)  
E-Mail [chengyi@jlu.edu.cn](mailto:chengyi@jlu.edu.cn)

LDL, MDA-LDL, GSH, and GSSG, and the GSH/GSSG ratio in healthy participants. In addition, no effects of the peroxidation reaction system of MPO (PRSM) and the chlorination reaction system of MPO (CRSM) on GSH/GSSG were found in this investigation. However, we found that the PRSM rather than the CRSM correlated with progressive low-density lipoprotein (LDL) modifications by HNE-LDL and MDA-LDL in atherosclerotic patients with hypertension.

**Conclusion:** The PRSM rather than the CRSM correlated with progressive LDL modifications via reactive aldehydes in atherosclerotic patients with hypertension. Further investigation is warranted to evaluate whether the PRSM may serve as a potential index for monitoring LDL function in atherosclerosis and hypertension.

© 2018 The Author(s)  
Published by S. Karger AG, Basel

## Introduction

Cardiovascular diseases are major causes of mortality in industrialized countries, although advances have been made in the control of coronary risk factors. Abnormalities in the metabolism of lipids are involved in the development of atherosclerosis and hypertension [1]. Reactive oxygen species (ROS) contribute to the dysfunction of serum lipoproteins, thus triggering lipid metabolism abnormalities [2].

ROS generation is initiated by either nonenzymatic or enzymatic reactions. Oxidoreductases, such as myeloperoxidase (MPO) are widely expressed in neutrophils and monocytes and are a major class of enzymes that generate ROS. Neutrophils and monocytes are involved in atherogenesis and atherothrombosis because they can infiltrate the fibrous caps of ruptured plaques [3-5]. Unstable fibrous caps contain more MPO-positive cells (neutrophils and iron-containing macrophages) than stable fibrous caps. These MPO-positive cells in thrombi adjacent to disrupted plaques are also associated with occlusive thrombi [6]. MPO activates metalloproteinases, leading to the destabilization and rupture of the surfaces of atherosclerotic plaques [7, 8]. Interestingly, MPO binds to the surface of low-density lipoprotein (LDL), and causes the proatherogenic modification of LDL [9, 10]. Serum MPO levels correlate with the risk of coronary atherosclerosis [11]. Moreover, increased plasma MPO levels are observed in atherosclerotic patients [12, 13]. Plasma MPO levels are positively associated with systolic blood pressure (SBP) [14], while reductions in MPO levels correlate with the lowering of blood pressure [15]. Thus, MPO is implicated in both atherosclerosis and hypertension.

MPO catalyzes the conversion of hydrogen peroxide ( $H_2O_2$ ) and chloride ion ( $Cl^-$ ) to hypochlorous acid (HClO), which further generates ROS [16]. The MPO- $H_2O_2$ - $Cl^-$  system is involved in oxidative stress, which plays a critical role in the development of atherosclerosis and hypertension [17-20]. MPO activity is classified into peroxidation and chlorination. Interaction between MPO and  $H_2O_2$  causes single two-electron oxidation of MPO to compound I (MPO-I), thereby activating the peroxidation activity of MPO, which oxidizes various reducible substrates. Additionally, the interaction between MPO-I and  $Cl^-$  generates HClO, which confers the chlorination activity of MPO. Importantly,  $H_2O_2$  is essential for the peroxidation activity of MPO,  $H_2O_2$  and  $Cl^-$  are required for the chlorination activity, and the relative levels of the reducible substrates or  $Cl^-$  determine whether MPO inclines towards peroxidation or chlorination [21]. For this reason, the MPO- $H_2O_2$ - $Cl^-$  system is divided into the peroxidation reaction system of MPO (PRSM) and the chlorination reaction system of MPO (CRSM). The PRSM consists of MPO peroxidation activity and  $H_2O_2$ , and the CRSM comprises MPO chlorination activity,  $H_2O_2$ , and  $Cl^-$ .

An enzyme and its substrate(s) form the reaction system of the enzyme, although enzyme activity has mostly been a target reflecting the association between the enzyme and a disease. In fact, the reaction system rather than the enzyme activity itself represents the entire function of the enzyme. However, the reaction system of an enzyme in relation to a disease, which could be a new biomarker for diagnosis, has not been thoroughly investigated. Notably, the CRSM contributes to high-density lipoprotein (HDL) oxidative damage *in vivo* [22]. The shift of the interconnection from the reaction system of paraoxonase 1 to PRSM

with HDL cholesterol (HDL-C) levels is a marker of atherosclerosis in patients with normal cholesterol levels [23]. Thus, the MPO-H<sub>2</sub>O<sub>2</sub>-Cl<sup>-</sup> system could be a new comprehensive biomarker for the prediction of cardiovascular diseases.

Considering that the function of the PRSM has not been distinguished from that of the CRSM in cardiovascular diseases, and MPO is implicated in both atherosclerosis and hypertension, we investigated the association between the MPO-H<sub>2</sub>O<sub>2</sub>-Cl<sup>-</sup> system (PRSM and CRSM) and the oxidative status of serum from atherosclerotic patients with hypertension in this study.

## Materials and Methods

### *Study population*

This study included 190 subjects who had no infectious diseases (93 men and 97 women) in Northeast China. Patients with stenosis were confirmed by coronary angiography. Healthy control subjects (group 1) who had no atherosclerotic coronary diseases or risk factors for atherosclerosis-related diseases were also recruited. All patients and healthy controls were selected from the First Hospital of Jilin University and the General Hospital of Jilin Chemical Group Corporation. All coronary angiograms were visually assessed by three experienced angiographers, and a consensus was reached between them. The SYNTAX score was assessed using the internet-based SYNTAX calculator ([www.syntaxscore.com](http://www.syntaxscore.com)) [24]. The SYNTAX score is a tool for scoring the complexity of coronary artery disease, thus we selected three SYNTAX score ranges (10–22, 23–32, and ≥33), and divided the patients into groups 2, 3, or 4, respectively. Hypertension was determined by measuring blood pressure 3 times at weekly intervals (in a seated position after 5 min in a relaxed condition). Data obtained from all participants included SBP, diastolic blood pressure (DBP), Cl<sup>-</sup>, total cholesterol (TC), HDL-C, and LDL cholesterol (LDL-C). This study was approved by the Ethics Committee of the First Hospital of Jilin University or the General Hospital of Jilin Chemical Group Corporation, and written informed consent was obtained from each participant.

### *Detection of laboratory parameters*

Blood samples were obtained after an overnight 12-h fast. Whole blood samples were collected in Vacutainer tubes on admission. Serum was recovered after centrifugation at 4000 rpm for 5 min at 4°C. All aliquots of serum were mixed with an antioxidant solution (100 μmol/L butylated hydroxytoluene and 100 μmol/L diethylenetriaminepentaacetic acid) and stored in vacuum bags to minimize artificial oxidation at -80°C until analysis [25].

TC, HDL-C, LDL-C, and Cl<sup>-</sup> were measured by the clinical laboratory of the First Hospital of Jilin University. Circulating 4-hydroxynonenal-modified LDL (HNE-LDL) and malondialdehyde-modified LDL (MDA-LDL) were analyzed using OxiSelect™ Human Oxidized LDL ELISA Kits (Catalog number: STA-369 and STA-389; Cell Biolabs, Inc., San Diego, CA). MPO activity was measured using Myeloperoxidase Peroxidation Assay Kit and Myeloperoxidase Chlorination Assay Kit (Item No. 700160; Item No. 10006438, Cayman Chemical Company, Ann Arbor, MI).

Total glutathione and oxidized glutathione (GSSG) were determined using the enzymatic method [26]. Reduced glutathione (GSH) is the difference between total glutathione and GSSG.

### *Statistical analysis*

All recorded data, except SYNTAX scores, male sex, and current smoker status, were expressed as the mean ± standard deviation. The distribution of quantitative variables was tested for normality using a one-sample Kolmogorov-Smirnov test. The following quantitative variables were compared using independent-samples t tests: age, SBP, DBP, Cl<sup>-</sup>, TC, HDL-C, LDL-C, HNE-LDL, MDA-LDL, H<sub>2</sub>O<sub>2</sub>, GSH, GSSG, GSH/GSSG ratio, MPO chlorination activity, and MPO peroxidation activity. Because of H<sub>2</sub>O<sub>2</sub>, MPO peroxidation and chlorination activities were skewed; therefore, Spearman's correlation was used to investigate any correlation between the levels of oxidative and anti-oxidative stress-related indices (HNE-LDL, MDA-LDL, GSH, GSSG, and GSH/GSSG ratio) and the levels of H<sub>2</sub>O<sub>2</sub> and MPO peroxidation and chlorination activities. In addition, Pearson's correlation was used to investigate any correlation between Cl<sup>-</sup> and the levels of the oxidative and anti-oxidative stress-related indices. Response surface regression was used to investigate the

contributions of the PRSM and CRSM to the levels of HNE-LDL, MDA-LDL, and the GSH/GSSG ratio. Two-sided *P* values < 0.05 were considered statistically significant in all analyses. Pairwise differences between the groups were assessed using a Bonferroni correction (*P* < 0.016). Analyses were performed using SPSS version 13 (SPSS Inc., Chicago, IL), Statistica version 10 (TIBCO Software, Inc., Palo Alto, CA), and Minitab version 16 (Minitab, Inc., Sydney, Australia).

## Results

We investigated 45 control subjects (group 1) and 145 atherosclerotic patients with hypertension, who were divided into groups 2, 3, and 4 according to their SYNTAX scores (as described in the Methods). Smokers were present in each group, and there were more in groups 2, 3, and 4 than in group 1. However, no significant differences between group 1 and groups 2, 3, or 4 were observed (*P* = 0.16, 0.07, and 0.07, respectively). We found that TC levels in groups 2 and 4, as well as LDL-C levels in groups 2, 3, and 4, were significantly higher than in group 1 (all *P* < 0.016); TC levels in group 3 were no different from those in group 1 (*P* = 0.025); HDL-C levels were significantly lower in groups 3 and 4 than in group 1 (*P* < 0.016), but those in group 2 were no different from those in group 1 (*P* = 0.023) (Table 1).


Oxidative stress affects the pathogenesis of atherosclerosis and hypertension, thereby providing oxidative and anti-oxidative stress-related indices, including HNE-LDL, MDA-LDL, H<sub>2</sub>O<sub>2</sub>, GSH, GSSG, and the GSH/GSSG ratio for investigating cardiovascular diseases, [27–32]. We observed that the levels of GSH and GSSG in groups 2, 3, and 4 were no different to those in group 1. However, the levels of MDA-LDL, HNE-LDL, H<sub>2</sub>O<sub>2</sub>, and the GSH/GSSG ratio in groups 2, 3, and 4 were significantly different from those in group 1 (all *P* < 0.016). In agreement with the known lack of association between plasma MPO levels and the angiographic severity of coronary artery disease in patients with acute coronary syndrome [33], our results also showed that there were no significant differences in the MPO peroxidation and chlorination activities among the groups (Table 1). Moreover, the levels of the MPO peroxidation and chlorination activities, H<sub>2</sub>O<sub>2</sub>, and Cl<sup>-</sup> were not associated with the levels of HNE-LDL, MDA-LDL, GSH, GSSG, or the GSH/GSSG ratio (all *P* > 0.05) (Table 2). Thus the individual components in the MPO-H<sub>2</sub>O<sub>2</sub>-Cl<sup>-</sup> system did not affect the levels of the oxidative and anti-oxidative stress-related indices.

**Table 1.** Clinical and laboratory parameters in participants. Group 1: the healthy control participants; Group 2-4: the patients with SYNTAX score (1-22; 23-32; ≥33). SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HNE-LDL, 4-hydroxynonenal-modified LDL; MDA-LDL, malondialdehyde-modified LDL; GSH, reduced glutathione; GSSG, oxidized glutathione; MPO, myeloperoxidase. Data, except male gender, current smoker and current alcohol drinker, are expressed as mean ± standard deviation

Parameter	Group 1 (n=45)	Group 2 (n=57)	Group 3 (n=42)	Group 4 (n=46)	Group 2 vs Group 1	P Group 3 vs Group 1	Group 4 vs Group 1
SYNTAX score	-	10-22	23-32	≥33			
Age, years	54.3±9.1	56.6±8.5	57.3±7.9	56.5±9.3	0.191	0.105	0.257
Male gender (%)	24 (53.3)	31 (54.4)	22 (52.4)	26 (56.5)	0.925	0.899	0.924
Current smoker (%)	15 (33.3)	28 (49.1)	25 (59.5)	25 (54.3)	0.161	0.70	0.070
SBP (mm Hg)	115.5±8.7	164.6±13.1	166.4±15.9	165.9±16.1	<0.001	<0.001	<0.001
DBP (mm Hg)	77.5±9.2	101.4±7.2	105.8±9.6	107.9±6.3	<0.001	<0.001	<0.001
Cl <sup>-</sup> (mmol/L)	102.05±2.47	102.32±2.48	102.4±3	102.45±2.53	0.585	0.552	0.447
TC (mmol/L)	4.35±0.46	5.11±1.66	5.1±1.55	5.21±1.36	0.003	0.025	0.0001
HDL-C (mmol/L)	1.23±0.31	1.09±0.3	1.07±0.13	1.02±0.43	0.023	0.002	0.009
LDL-C (mmol/L)	2.68±0.32	3.49±0.52	3.68±0.75	3.75±0.62	<0.001	<0.001	<0.001
HNE-LDL (ng/mL)	2.77±0.56	3.48±0.98	4.33±1.45	5.75±1.98	<0.001	<0.001	<0.001
MDA-LDL (ng/mL)	2.81±0.43	3.26±0.84	3.29±0.91	3.54±1	0.001	0.002	<0.001
GSH (μmol/L)	451.9±107.17	429.9±89.25	453.93±157.21	432.01±93.1	0.261	0.943	0.346
GSSG (μmol/L)	45.79±10.69	44.32±9.17	47.52±16.83	45.36±9.69	0.456	0.565	0.841
GSH/GSSG ratio	9.87±0.24	9.7±0.19	9.57±0.34	9.53±0.24	0.001	<0.001	<0.001
H <sub>2</sub> O <sub>2</sub> (μmol/L)	3.38±0.7	4.09±0.96	4.37±1.07	4.19±0.95	<0.001	<0.001	<0.001
MPO peroxidation activity (ng/mL)	29.4±6.18	32.28±9.73	28.4±11.35	29.65±9.21	0.087	0.607	0.879
MPO chlorination activity (ng/mL)	23.18±1.72	23.23±1.91	23.3±1.54	23.06±1.87	0.891	0.733	0.751

**Table 2.** Correlation between the individual factor in MPO reaction system and the levels of oxidative and anti-oxidative stress-related indices. HNE-LDL, 4-hydroxynonenal-modified LDL; MDA-LDL, malondialdehyde-modified LDL; GSH, reduced glutathione; GSSG, oxidized glutathione; MPO, myeloperoxidase

Parameter	MPO peroxidation activity (ng/mL)		MPO chlorination activity (ng/mL)		H <sub>2</sub> O <sub>2</sub> (μmol/L)		Cl <sup>-</sup> (mmol/L)	
	r	(P-value)	r	(P-value)	r	(P-value)	r	(P-value)
HNE-LDL (ng/mL)	-0.008	(0.911)	--0.083	(0.256)	0.019	(0.797)	0.02	(0.788)
MDA-LDL (ng/mL)	0.008	(0.912)	0.037	(0.613)	0.072	(0.322)	0.011	(0.882)
GSH (μmol/L)	-0.021	(0.769)	-0.087	(0.232)	-0.023	(0.753)	0.021	(0.772)
GSSG (μmol/L)	-0.023	(0.751)	-0.073	(0.316)	-0.014	(0.853)	0.015	(0.837)
GSH/GSSG ratio	-0.06	(0.412)	-0.06	(0.412)	-0.052	(0.477)	-0.006	(0.934)



**Fig. 1.** Contributions of PRSM to the trend surface of HNE-LDL (A), MDA-LDL (B), and GSH/GSSG (C) in all patients.

We next focused on whether the MPO-H<sub>2</sub>O<sub>2</sub>-Cl<sup>-</sup> system (PRSM and/or CRSM) is associated with the levels of HNE-LDL, MDA-LDL, or the GSH/GSSG ratio. We found that the PRSM was associated with HNE-LDL and MDA-LDL values rather than the GSH/GSSG ratio in all patients (Fig. 1). We further used response surface regression to investigate the relationships between the MPO-H<sub>2</sub>O<sub>2</sub>-Cl<sup>-</sup> system and the levels of HNE-LDL, MDA-LDL, and the GSH/GSSG ratio. Our results showed no correlation between the PRSM and the levels of HNE-LDL, MDA-LDL, and the GSH/GSSG ratio in group 1 (all *P* > 0.05) (Table 3). The interaction between H<sub>2</sub>O<sub>2</sub> levels



**Table 3.** Association between MPO reaction system and the level of HNE-LDL, MDA-LDL and GSH/GSSG ratio. Group 1: the subjects with SYNTAX score (0-5); Group 2-4: the patients with SYNTAX score (6-22; 23-32; ≥33). Coef, coefficient; SE, standard error of coefficient; MPO, myeloperoxidase; CRSM, the chlorination reaction system of MPO; PRSM, the peroxidation reaction system of MPO; MPO, myeloperoxidase; GSH, reduced glutathione; GSSG, oxidized glutathione; HNE-LDL, 4-hydroxynonenal-modified LDL; MDA-LDL, malondialdehyde-modified LDL. \* represented interaction

Group	Reaction system	HNE-LDL			MDA-LDL			GSH/GSSG ratio		
		Coef±	SE	P	Coef±	SE	P	Coef±	SE	P
1	CRSM									
	MPO Chlorination activity (ng/mL)	-0.15±	0.22	0.489	-0.1±	0.16	0.541	-0.03±	0.04	0.76
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	0.26±	0.3	0.404	0.04±	0.23	0.871	-0.02±	0.13	0.861
	Cl <sup>-</sup> (mmol/L)	-0.14±	0.26	0.585	-0.15±	0.19	0.436	0.12±	0.11	0.257
	MPO Chlorination activity * H <sub>2</sub> O <sub>2</sub>	-0.04±	0.41	0.916	-0.18±	0.31	0.566	-0.19±	0.17	0.273
	MPO Chlorination activity * Cl <sup>-</sup>	-0.21±	0.3	0.497	-0.32±	0.23	0.168	-0.16±	0.13	0.217
	H <sub>2</sub> O <sub>2</sub> * Cl <sup>-</sup>	-0.18±	0.48	0.709	-0.7±	0.36	0.056	-0.03±	0.2	0.876
	PRSM									
	MPO Peroxidation activity (ng/mL)	0.5±	0.29	0.095	0.2±	0.23	0.387	-0.11±	0.13	0.381
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	0.14±	0.29	0.618	-0.13±	0.22	0.556	0.1±	0.12	0.419
	MPO Peroxidation activity * H <sub>2</sub> O <sub>2</sub>	0.75±	0.47	0.12	-0.09±	0.37	0.813	0.25±	0.2	0.223
2	CRSM									
	MPO Chlorination activity (ng/mL)	-0.15±	0.32	0.641	0.2±	0.29	0.49	-0.02±	0.07	0.721
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	-0.17±	0.28	0.536	0.43±	0.25	0.095	0.03±	0.06	0.776
	Cl <sup>-</sup> (mmol/L)	-0.24±	0.3	0.427	-0.22±	0.27	0.416	0.12±	0.11	0.26
	MPO Chlorination activity * H <sub>2</sub> O <sub>2</sub>	-0.33±	0.51	0.522	0.12±	0.47	0.792	0.08±	0.12	0.472
	MPO Chlorination activity * Cl <sup>-</sup>	-0.39±	0.55	0.485	-0.07±	0.5	0.889	0.05±	0.08	0.568
	H <sub>2</sub> O <sub>2</sub> * Cl <sup>-</sup>	0.16±	0.48	0.738	0.46±	0.44	0.299	0.03±	0.1	0.773
	PRSM									
	MPO Peroxidation activity (ng/mL)	0.28±	0.36	0.439	-0.32±	0.13	0.34	0.04±	0.08	0.63
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	0.27±	0.27	0.328	0.46±	0.25	0.067	-0.02±	0.06	0.731
	MPO Peroxidation activity * H <sub>2</sub> O <sub>2</sub>	1.94±	0.77	0.016	0.3±	0.7	0.673	-0.16±	0.17	0.338
3	CRSM									
	MPO Chlorination activity (ng/mL)	-0.42±	0.99	0.669	0.9±	0.58	0.128	-0.11±	0.22	0.623
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	0.08±	0.654	0.901	0.61±	0.38	0.118	-0.1±	0.15	0.507
	Cl <sup>-</sup> (mmol/L)	-0.43±	0.66	0.52	0.42±	0.39	0.283	0.02±	0.15	0.865
	MPO Chlorination activity * H <sub>2</sub> O <sub>2</sub>	0.57±	1.5	0.705	0.57±	0.88	0.522	0.19±	0.34	0.572
	MPO Chlorination activity * Cl <sup>-</sup>	0.2±	1.46	0.894	0.14±	0.86	0.873	0.07±	0.33	0.821
	H <sub>2</sub> O <sub>2</sub> * Cl <sup>-</sup>	0.06±	0.87	0.942	0.01±	0.51	0.979	-0.35±	0.2	0.087
	PRSM									
	MPO Peroxidation activity (ng/mL)	-0.52±	0.48	0.281	-0.18±	0.3	0.548	-0.04±	0.12	0.754
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	-0.61±	0.52	0.254	0.61±	0.33	0.073	0.01±	0.13	0.946
	MPO Peroxidation activity * H <sub>2</sub> O <sub>2</sub>	-2.94±	1.28	0.027	1.7±	0.81	0.042	0.48±	0.32	0.166
4	CRSM									
	MPO Chlorination activity (ng/mL)	-0.1±	1.6	0.95	0.46±	0.89	0.608	0.21±	0.2	0.322
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	-0.42±	1.29	0.745	0.16±	0.71	0.825	0.1±	0.16	0.531
	Cl <sup>-</sup> (mmol/L)	-1.9±	1.52	0.220	-1.36±	0.83	0.111	-0.11±	0.19	0.591
	MPO Chlorination activity * H <sub>2</sub> O <sub>2</sub>	-0.3±	1.5	0.842	-0.33±	0.82	0.695	0.26±	0.19	0.178
	MPO Chlorination activity * Cl <sup>-</sup>	-0.09±	2.82	0.975	0.77±	1.55	0.624	0.5±	0.36	0.168
	H <sub>2</sub> O <sub>2</sub> * Cl <sup>-</sup>	2.7±	2.4	0.266	1.66±	1.31	0.214	-0.07±	0.3	0.813
	PRSM									
	MPO Peroxidation activity (ng/mL)	-0.67±	0.74	0.369	-0.49±	0.4	0.23	0.06±	0.1	0.519
	H <sub>2</sub> O <sub>2</sub> (μmol/L)	-1.83±	0.62	0.005	-0.71±	0.33	0.038	0.08±	0.08	0.335
	MPO Peroxidation activity * H <sub>2</sub> O <sub>2</sub>	-1.5±	1.3	0.256	-1.17±	0.7	0.103	-0.04±	0.17	0.821

and MPO peroxidation activity based on the PRSM was significantly associated with HNE-LDL levels in group 2 ( $P = 0.016$ ). Moreover, the interaction between H<sub>2</sub>O<sub>2</sub> levels and the MPO peroxidation activity in the PRSM was significantly associated with the levels of HNE-LDL and MDA-LDL in group 3 ( $P = 0.027$  and  $0.042$ , respectively). Intriguingly, H<sub>2</sub>O<sub>2</sub> levels, rather than the interaction between H<sub>2</sub>O<sub>2</sub> levels and MPO peroxidation activity, were significantly associated with the levels of HNE-LDL and MDA-LDL in group 4 ( $P = 0.005$  and  $0.038$ , respectively) (Table 3). However, no association between the PRSM and GSH/GSSG ratio was observed in any group. The CRSM was not associated with the levels of HNE-LDL, MDA-LDL, or the GSH/GSSG ratio in any group (Table 3). As expected, the adjusted coefficients of determination ( $r^2$ -adj) of the CRSM remained zero in each group. Neither the PRSM nor the CRSM were related to the GSH/GSSG ratio ( $r^2$ -adj = 0) (Table 4). Strikingly, the PRSM contributed to

the increasing trend of the adjusted coefficients of determination ( $r^2$ -adj) to the levels of HNE-LDL and MDA-LDL from group 2 to group 4, indicating a correlating factor between PRSM and progressive LDL modifications through reactive aldehydes in atherosclerotic patients with hypertension.

## Discussion

Our results established that the PRSM rather than the CRSM is associated with the levels of aldehyde-modified LDL in atherosclerotic patients with hypertension. Thus, the CRSM might not contribute to the levels of aldehyde-modified LDLs. The present study, therefore, identified differences in the effects of the PRSM and CRSM in the comorbidity of atherosclerosis and hypertension.

Previous studies have focused on either MPO protein levels or MPO activity in cardiovascular diseases. MPO protein levels predict risk in patients with acute coronary syndromes [34, 35]. However, large differences in the median concentrations of MPO create difficulties in ascertaining the normal MPO values of healthy individuals [36]. Increased MPO activity is associated with an oxidant-antioxidant imbalance that may contribute to atherosclerosis [37]. MPO, which binds to the surfaces of LDLs [9], is involved in lipid peroxidation, oxidative modification of LDL, and the formation of aldehydes *in vivo* [38-40]. Our results suggested that the function of the PRSM correlates with the levels of aldehyde-modified LDL in atherosclerotic patients with hypertension, although we found no association between any individual component in the MPO-H<sub>2</sub>O<sub>2</sub>-Cl system or the oxidative and anti-oxidative stress-related indices (HNE-LDL, MDA-LDL, GSH, GSSG, and the GSH/GSSG ratio).

PRSM is comprised of MPO and H<sub>2</sub>O<sub>2</sub>. H<sub>2</sub>O<sub>2</sub> is an upstream molecule in the cascade of oxidative stress and initiates the generation of ROS. H<sub>2</sub>O<sub>2</sub> levels positively correlate with the lipid peroxidation products of LDLs [41]. Lipid peroxidation caused by ROS generates MDA and HNE, which further modify LDL to form HNE-LDL and MDA-LDL. Moreover, MDA-LDL has been shown to be present in significantly higher levels in patients with acute coronary syndromes and stable coronary disease [42]. Consistent with the discovery that elevated H<sub>2</sub>O<sub>2</sub> levels in blood plasma is a pathogenic factor in vascular organ damage in systemic hypertension [43], our data showed substantial differences in serum H<sub>2</sub>O<sub>2</sub> levels between the control subjects and patients. Because the interaction between H<sub>2</sub>O<sub>2</sub> levels and the MPO peroxidation activity in PRSM was significantly associated with the levels of HNE-LDL and MDA-LDL, the interaction may indicate that MPO enhances the use of H<sub>2</sub>O<sub>2</sub> to counteract increasing H<sub>2</sub>O<sub>2</sub> levels in all patients. However, in group 4, the substantial association between H<sub>2</sub>O<sub>2</sub> levels and those of HNE-LDL and MDA-LDL suggested that MPO does not adequately mediate resistance to high H<sub>2</sub>O<sub>2</sub> levels.

H<sub>2</sub>O<sub>2</sub> is required for the conversion of GSH to GSSG, which is catalyzed by glutathione peroxidase. The GSH/GSSG ratios were substantially different between patients and control subjects, although the levels of GSH and GSSG were no different. However, the PRSM and CRSM did not contribute to the GSH/GSSG ratio in this study, suggesting that they may modify LDL, which binds to MPO.

Our study had several limitations. First, the formation of HClO from H<sub>2</sub>O<sub>2</sub> and Cl<sup>-</sup> is catalyzed by MPO, which is present only in phagocytic cells of the immune system (predominantly neutrophils). HClO is a powerful toxin that destroys bacteria within seconds

**Table 4.** Contribution of MPO reaction system to the level of HNE-LDL, MDA-LDL and GSH/GSSG ratio in each group. Group 1: the subjects with SYNTAX score (0-5); Group 2-4: the patients with SYNTAX score (6-22; 23-32; ≥33). PRSM, the peroxidation reaction system of MPO; CRSM, the chlorination reaction system of MPO. Data were the adjusted coefficients of determination ( $r^2$ -adj) that were calculated using response surface regression

Parameter	Group 1		Group 2		Group 3		Group 4	
HNE-LDL								
PRSM	0	.019	0	.07	0	.083	0	.155
CRSM			0		0		0	.05
MDA-LDL								
PRSM	0	.013	0	.041	0	.066	0	.116
CRSM			0		0		0	
GSH/GSSG ratio								
PRSM			0		0		0	
CRSM			0		0		0	

through halogenation and oxidation reactions. We excluded subjects with infectious diseases, and thereby possibly limited the CRSM function. However, we did not further measure HClO or chlorinated tyrosine levels to confirm that the function of CRSM was limited. Second, the low numbers of patients and healthy controls might have an impact on the level of statistical significance among some important variables. Third, because the degree of smoking affects the oxidative state, our study was not large enough to exclude the effect of smoking on the PRSM [44], although the patients in groups 2–4 showed no significant differences compared with the control participants in group 1. Fourth, the TC levels in group 3 showed no significantly different changes compared with those in group 1. This result was likely due in part to the SYNTAX score, which is a tool to score the complexity of coronary artery disease rather than to reflect TC levels. Fifth, medications taken by some patients might have affected the functions of the PRSM and CRSM.

Our investigation highlighted the conversion of  $H_2O_2$  in sera. The conversion of  $H_2O_2$  involves the participation of MPO, catalase, glutathione peroxidase, ferrous ion, and cuprous ion. Importantly, ferrous ion and cuprous ion convert  $H_2O_2$  into a hydroxyl radical, which is the most reactive species generated among MDA and HNE, and the MPO- $H_2O_2$ -Cl<sup>-</sup> system only contributes partially to  $H_2O_2$  conversion. Moreover, MPO-I directly transformed to MPO, instead bypassing an interaction with Cl<sup>-</sup>, indicating that the MPO peroxidation activity is more efficient and direct than MPO chlorination activity in the conversion of  $H_2O_2$ . Therefore, the PRSM, rather than the CRSM, correlated with progressive LDL modification via reactive aldehydes in atherosclerotic patients with hypertension. Further investigation is warranted to evaluate whether the PRSM may serve as a potential index that will enable LDL function to be monitored in atherosclerosis and hypertension.

## Acknowledgements

This work was supported by the funds from the National Natural Science Foundation of China (81573230) and the National Key Research and Development Project of Precision Medicine (2016YFC0900903). We gratefully acknowledge Prof. Junqi Niu (Department of Hepatology), Dr. Xiaoyi Xu and Dr. Dehai Yu (Department of Hematology and Oncology), and the First Hospital of Jilin University for the kind provision of technical assistance.

## Disclosure Statement

The corresponding author states on behalf of all authors that there were no conflicts of interest. No research funding was provided for the study design, collection of data, study analyses, interpretation of data, writing of the report, or the decision to submit the report for publication.

## References

- 1 Bonomini F, Rodella LF, Rezzani R: Metabolic syndrome, aging and involvement of oxidative stress. *Aging Dis* 2015;6:109-120.
- 2 Stefanutti C, Thompson GR: Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. *Curr Atheroscler Rep* 2015;17:465.
- 3 Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB: Which white blood cell subtypes predict increased cardiovascular risk? *J Am Coll Cardiol* 2005;45:1638-1643.
- 4 Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Neutrophil infiltration of culprit lesions in acute coronary syndromes. *Circulation* 2002;106:2894-2900.



- 5 Manoharan G, Ntalianis A, Muller O, Hamilos M, Sarno G, Melikian N, Vanderheyden M, Heyndrickx GR, Wyffels E, Wijns W, De Bruyne B: Severity of coronary arterial stenoses responsible for acute coronary syndromes. *Am J Cardiol* 2009;103:1183-1188.
- 6 Tavora FR, Ripple M, Li L, Burke AP: Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. *BMC Cardiovasc Disord* 2009;9:27.
- 7 Fu X, Kassim SY, Parks WC, Heinecke JW: Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. *J Biol Chem* 2001;276:41279-41287.
- 8 Ferrante G, Nakano M, Prati F, Niccoli G, Mallus MT, Ramazzotti V, Montone RA, Kolodgie FD, Virmani R, Crea F: High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. *Circulation* 2010;122:2505-2513.
- 9 Sokolov AV, Kostevich VA, Runova OL, Gorudko IV, Vasilyev VB, Cherenkevich SN, Panasenka OM: Proatherogenic modification of LDL by surface-bound myeloperoxidase. *Chem Phys Lipids* 2014;180:72-80.
- 10 Delporte C, Boudjeltia KZ, Noyon C, Furtmuller PG, Nuyens V, Slomianny MC, Madhoun P, Desmet JM, Raynal P, Dufour D, Koyani CN, Reye F, Rousseau A, Vanhaeverbeek M, Ducobu J, Michalski JC, Neve J, Vanhamme L, Obinger C, Malle E, Van Antwerpen P: Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100. *J Lipid Res* 2014;55:747-757.
- 11 Malle E, Furtmuller PG, Sattler W, Obinger C: Myeloperoxidase: a target for new drug development? *Br J Pharmacol* 2007;152:838-854.
- 12 Klebanoff SJ: Myeloperoxidase. *Proc Assoc Am Physicians* 1999;111:383-389.
- 13 Jaremo P, Hansson G, Nilsson O: Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST-elevation. *Thromb Res* 2000;100:471-478.
- 14 Derosa G, D'Angelo A, Mugellini A, Pesce RM, Fogari E, Maffioli P: Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. *Curr Med Res Opin* 2012;28:1435-1445.
- 15 Van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CD, Heine RJ, Teerlink T: Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. *Hypertension* 2010;55:1366-1372.
- 16 Klebanoff SJ: Myeloperoxidase: friend and foe. *J Leukoc Biol* 2005;77:598-625.
- 17 Karakas M, Koenig W: Myeloperoxidase production by macrophage and risk of atherosclerosis. *Curr Atheroscler Rep* 2012;14:277-283.
- 18 de Champlain J, Wu R, Girouard H, Karas M, A ELM, Laplante MA, Wu L: Oxidative stress in hypertension. *Clin Exp Hypertens* 2004;26:593-601.
- 19 Pattison DJ, Davies MJ: Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. *Curr Med Chem* 2006;13:3271-3290.
- 20 Stacey MM, Cuddihy SL, Hampton MB, Winterbourn CC: Protein thiol oxidation and formation of S-glutathionylated cyclophilin A in cells exposed to chloramines and hypochlorous acid. *Arch Biochem Biophys* 2012;527:45-54.
- 21 Nguyen JB, Pool CD, Wong CY, Treger RS, Williams DL, Cappello M, Lea WA, Simeonov A, Vermeire JJ, Modis Y: Peroxiredoxin-1 from the human hookworm *Ancylostoma ceylanicum* forms a stable oxidized decamer and is covalently inhibited by conoidin A. *Chem Biol* 2013;20:991-1001.
- 22 Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E: Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. *J Biol Chem* 2002;277:32172-32179.
- 23 Wang F, Liu Y, Cong Y, Li P, Li Y, Yan Z, Tang Y, Cheng Y, Zheng Y: Shift of the interconnection from the reaction system of paraoxonase 1 to the peroxidation reaction system of myeloperoxidase with HDL-C levels: a marker of atherosclerosis in patients with normal cholesterol levels. *Clin Chim Acta* 2015;438:370-375.
- 24 Sinning C, Lillpopp L, Appelbaum S, Ojeda F, Zeller T, Schnabel R, Lubos E, Jagodzinski A, Keller T, Munzel T, Bickel C, Blankenberg S: Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. *Clin Res Cardiol* 2013;102:495-503.

- 25 Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL: Statins promote potent systemic antioxidant effects through specific inflammatory pathways. *Circulation* 2003;108:426-431.
- 26 Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. *Anal Biochem* 1969;27:502-522.
- 27 Schulz E, Gori T, Munzel T: Oxidative stress and endothelial dysfunction in hypertension. *Hypertens Res* 2011;34:665-673.
- 28 Malle E, Ibovnik A, Leis HJ, Kostner GM, Verhallen PF, Sattler W: Lysine modification of LDL or lipoprotein(a) by 4-hydroxynonenal or malondialdehyde decreases platelet serotonin secretion without affecting platelet aggregability and eicosanoid formation. *Arterioscler Thromb Vasc Biol* 1995;15:377-384.
- 29 Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griending KK: Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. *Arterioscler Thromb Vasc Biol* 2002;22:21-27.
- 30 Lopes PA, Napoleao P, Pinheiro T, Ceia F, Steghens JP, Pavao ML, Santos MC, Viegas-Crespo AM: Systemic markers of the redox balance and apolipoprotein E polymorphism in atherosclerosis: the relevance for an integrated study. *Biol Trace Elem Res* 2006;112:57-75.
- 31 Schutte R, Schutte AE, Huisman HW, van Rooyen JM, Malan NT, Peter S, Fourie CM, van der Westhuizen FH, Louw R, Botha CA, Malan L: Blood glutathione and subclinical atherosclerosis in African men: the SABPA Study. *Am J Hypertens* 2009;22:1154-1159.
- 32 Wang Y, Chun OK, Song WO: Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. *Nutrients* 2013;5:2969-3004.
- 33 de Azevedo Lucio E, Goncalves SC, Ribeiro JP, Nunes GL, de Oliveira JR, Araujo GN, Wainstein MV: Lack of association between plasma myeloperoxidase levels and angiographic severity of coronary artery disease in patients with acute coronary syndrome. *Inflamm Res* 2011;60:137-142.
- 34 Brennan ML, Hazen SL: Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. *Curr Opin Lipidol* 2003;14:353-359.
- 35 Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. *Circulation* 2003;108:1440-1445.
- 36 Strobel NA, Fassett RG, Marsh SA, Coombes JS: Oxidative stress biomarkers as predictors of cardiovascular disease. *Int J Cardiol* 2011;147:191-201.
- 37 Begenik H, Soyoral YU, Erkoc R, Emre H, Taskin A, Tasdemir M, Aslan M: Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome. *Redox Rep* 2013;18:107-112.
- 38 Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. *J Biol Chem* 2002;277:46116-46122.
- 39 Kraemer T, Prakosay I, Date RA, Sies H, Schewe T: Oxidative modification of low-density lipoprotein: lipid peroxidation by myeloperoxidase in the presence of nitrite. *Biol Chem* 2004;385:809-818.
- 40 Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, Spitz DR, Topol EJ, Hazen SL, Penn MS: Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. *Circulation* 2005;112:2812-2820.
- 41 Hsu SP, Wu MS, Yang CC, Huang KC, Liou SY, Hsu SM, Chien CT: Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines. *Am J Clin Nutr* 2007;86:1539-1547.
- 42 Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. *Circulation* 1998;98:1487-1494.
- 43 Lacy F, O'Connor DT, Schmid-Schonbein GW: Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. *J Hypertens* 1998;16:291-303.
- 44 Zuo L, He F, Sergakis GG, Koozehchian MS, Stimpfl JN, Rong Y, Diaz PT, Best TM: Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. *Am J Physiol Lung Cell Mol Physiol* 2014;307:L205-218.